Five-year Weight Loss Maintenance With Obesity Pharmacotherapy
Authors' conclusion
Clinically significant long-term weight loss of 10% or more beyond 4 years is achievable in clinical practice settings with obesity pharmacotherapy.
Study context
- Population
- Patients with overweight or obesity treated with antiobesity medications (AOMs) at an academic weight management center, initial visit April 1, 2014–April 1, 2016
- Participants
- 428 patients
- Outcome
- Percentage weight loss from initial to final visit
- Follow-up
- Mean 4.4 years
Methodological detailsreal-world, single academic weight management center
- Real-world
- Single academic weight management center
Main finding
As reported in the abstract
Average weight loss
10.4%
Observational data: associations, not effects.
Secondary outcomes
Weight reduction targets met (≥5%, ≥10%, ≥15%, ≥20%)
- ≥5% weight loss
- 70.8%
- ≥10% weight loss
- 48.1%
- ≥15% weight loss
- 29.9%
- ≥20% weight loss
- 17.1%
Weight regain and maintenance
- Mean share of maximum weight loss regained
- 51%
- Patients who maintained their weight loss
- 40.2%
Predictors of long-term weight loss (multivariable regression)
- Higher number of clinic visits associated with more weight loss
- Metformin, topiramate and bupropion associated with increased odds of maintaining ≥10% weight loss
Original publication
Five-year Weight Loss Maintenance With Obesity Pharmacotherapy. J Clin Endocrinol Metab. Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →